Skip to main content

Table 3 Factors associated with adequate beta-lactam concentration (> 4 times the MIC threshold)

From: Impact of renal replacement therapy strategy on beta-lactam plasma concentrations: the BETAKIKI study—an ancillary study of a randomized controlled trial

 

Univariate analysis

Multivariate analysis

 

Inadequate (N = 22)

Adequate (N = 90)

p value

OR [CI 95%]

p value

Sex (female), N (%)

7 (31.8)

29 (32.2)

0.97

  

Age (year), mean (SD)

67.0 (10.0)

64.3 (13.7)

0.57

  

Weight (kg), mean (SD)

84.5 (12.8)

86.1 (20.9)

0.67

  

Delay between ICU admission and randomization, median [IQ]

1.5 [1–4.75]

1 [1, 2]

   

Chronic kidney disease, N (%)

0 (0)

7 (7.8)

0.34

  

Delayed strategy group (AKIKI randomization), N (%)

11 (50)

48 (53.3%)

0.78

1.18 [0.40–3.45]

0.767

SAPS III, mean (SD)

70.0 (8.4)a

70.7 (14.4)b

0.97

  

Administration of aminoglycosides

4/14 (28.6%)

33/56 (58.9%)

0.04

2.24 [0.58–8.72]

0.23

Administration of vancomycin

1/14 (7.1%)

11/56 (19.6%)

0.43

  

Septic shock, N (%)

10 (45.5)

73 (81.1)

0.0006

3.95 [1.14–13.64]

0.029

Mean arterial pressure (mmHg), mean (SD)

70 (7)

77 (16)

0.0181

1.05 [1.01–1.10]

0.013

Cardiac rate (beats per minute), mean (SD)

99 (24)

111 (28)

0.053

  

Serum creatinine (µM), mean (SD)

231.3 (100.8)

289.6 (112.5)

0.024

1.01 [1.00–1.01]

0.062

Serum urea (mM), mean (SD)

17.6 (8.2)

18.5 (8.0)

0.82

  

Serum bicarbonate (mM), mean (SD)

21.3 (5.6)

19.0 (4.4)a

0.045

0.97 [0.86–1.09]

0.585

Arterial blood lactate (mM), mean (SD)

2.5 (1.8)c

2.7 (2.4)d

0.98

  
  1. Bold values specifies the statistically significant variables in the multivariate analysis
  2. a1 missing data
  3. b6 missing data
  4. c3 missing data
  5. d8 missing data